View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 30, 2021

Boehringer and Lilly report positive data from EMPEROR-Preserved trial

The trial tested the safety and efficacy of Jardiance in patients with chronic HFpEF.

Boehringer Ingelheim and Eli Lilly and Company (Lilly) have reported positive data from the EMPEROR-Preserved Phase III trial.

The trial evaluated the safety and efficacy of Jardiance (empagliflozin) in patients with chronic heart failure with preserved ejection fraction (HFpEF).

In the trial, Jardiance demonstrated 21% reduction in risk of cardiovascular death or hospitalisation for heart failure in adults with HFpEF compared with placebo.

Additionally, the medication reduced the relative risk of first and recurrent hospitalisations for heart failure by 27%. Jardiance also decelerated the decline in kidney function.

The result was independent of ejection fraction or diabetes status.

Boehringer and Lilly have presented the results at the European Society of Cardiology (ESC) Congress 2021 and published it in The New England Journal of Medicine.

EMPEROR-Preserved principal investigator and Charité Berlin heart failure cardiologist Stefan Anker said: “For people with heart failure with preserved ejection fraction, the reality is that so far there are no clinically proven treatments we can offer that would make a significant impact on their condition.

“This data brings hope for millions of patients suffering from heart failure with a preserved ejection fraction. The primary endpoint was similarly improved in all subgroups of patients, in men and women, with and without diabetes, and regardless of their ejection fraction and kidney function level.”

Overall, the trial included 5,988 people with heart failure including 4,005 with a left ventricular ejection fraction (LVEF) of 50% or above.

The results were consistent with those of the EMPEROR-Reduced trial that assessed the efficacy of Jardiance in patients with chronic heart failure with reduced ejection fraction (HFrEF).

Recently, the US Food and Drug Administration (FDA) approved Jardiance for reduction of risk of cardiovascular death plus hospitalisation for heart failure in adults with HFrEF.

Currently, the medicine is also being tested for chronic kidney disease.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy